Table 1. Characteristics of the included studies.
| First author | Year | Study design | Patient source | N (F/M) | Mean age | No. of eyes | Normal RNFL | Thin RNFL | Tumor type | Surgical approach | RNFL cut-off# | Vision test | Follow- up time | OR adjusted | Attitude |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Danesh-Meyer | 2008 | prospective | New Zealand/USA | 35 (18/17) | 45 | 63 | 43 | 20 | mixed* | not reported | 97.5% | VF | ≤6W | no | positive& |
| Danesh-Meyer | 2015 | prospective | Australia | 107 (49/58) | 53.67 | 213 | 178 | 35 | PA | both | 95% | VA | 9–15M | no | positive |
| Park | 2015 | retrospective | Korea | 25 (23/2) | 51.5 | 49 | 28 | 21 | meningioma | transcranial | 95% | VF | 3.1–31.7M | no | positive |
| Yoneoka | 2015 | prospective | Japan | 35 (13/22) | 57.6 | 70 | 45 | 25 | PA | transsphenoidal | 99% | VF | ≥3M | yes | positive |
N (F/M) number of patients (Female/Male), RNFL retinal nerve fiber layer, PA pituitary adenoma, VF visual field, VA visual acuity, W weeks, M months, OR odds ratio.
* mixed: 27 pituitary adenoma, 3 cystic lesions, 2 meningioma, 1 craniopharyngioma, 1 neurosarcoidosis, 1 paraclinoid aneurysm;
# RNFL cut-off: thinner than 99%/97.5%/95% of normative values obtained from the manufacturer's database;
& positive: normal RNFL thickness predicted better visual recovery.